☆ 4.7 Editorial Material

Severe Hypophosphatemia: The Hidden Truth

CLINICAL CHEMISTRY (2023)

Tumor-induced Osteomalacia: A Systematic Review and Individual Patient's Data Analysis

Domenico Rendina et al.

Summary: Tumor-induced osteomalacia (TIO) is more common in adult men and is mainly caused by phosphaturic mesenchymal tumors. Surgery is the preferred treatment for TIO, but promising nonsurgical therapies such as burosumab and radiolabeled somatostatin analogs have shown potential efficacy.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2022)

添加到收藏夹

Article Endocrinology & Metabolism

Burosumab for the Treatment of Tumor-Induced Osteomalacia

Suzanne M. Jan de Beur et al.

Summary: The study demonstrated that burosumab exhibited an acceptable safety profile in adult patients with TIO and was associated with improvements in phosphate metabolism and osteomalacia.

JOURNAL OF BONE AND MINERAL RESEARCH (2021)

添加到收藏夹

Article Endocrinology & Metabolism

Diagnosis and Management of Tumor-induced Osteomalacia: Perspectives From Clinical Experience

Kathryn Dahir et al.

Summary: TIO is a rare paraneoplastic syndrome caused by small endocrine tumors secreting FGF23, leading to musculoskeletal pain, fatigue, muscle weakness, and fractures. Prompt diagnosis of TIO requires laboratory tests, imaging, and surgical resection for cure. Awareness and education among healthcare professionals are crucial to improve management of this debilitating disease.

JOURNAL OF THE ENDOCRINE SOCIETY (2021)

添加到收藏夹

Article Endocrinology & Metabolism